Anti-Human CD52 (Alemtuzumab) – Fc Muted™ HRP

Anti-Human CD52 (Alemtuzumab) – Fc Muted™ HRP

Product No.: LT207

- -
- -
Product No.LT207
Clone
Campath-1H
Target
CD52
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
HE5; CDW52; EDDM5 CDW52; Cambridge pathology 1 antigen
Isotype
Human IgG1κ
Applications
ELISA
,
FA
,
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Cynomolgus Monkey
Rhesus Monkey
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Muted
Immunogen
Human lymphocytes.
Product Concentration
0.5 mg/ml
Formulation
This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Storage and Handling
This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
FA
ELISA
Additional Reported Applications For Relevant Conjugates ?
CyTOF®
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only.
Background
Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects.
Antigen Distribution
CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted.
PubMed
NCBI Gene Bank ID
Research Area
Biosimilars

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Research-grade Alemtuzumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA by preparing serial dilutions of the biosimilar in human serum or plasma to create a calibration curve, which is then used to quantify alemtuzumab concentrations in patient samples through comparison with these standards.

Essential context and details:

  • Calibration Standards Preparation: Calibration standards are typically made by serially diluting a reference-grade alemtuzumab biosimilar (from single or multiple batches) in human serum or plasma, matching the matrix of patient samples to ensure accuracy and account for any matrix effects.
  • Lot Comparison and Validation: Multiple batches of the biosimilar may be used as calibration standards to ensure consistency and to exclude differences between lots. Their concentrations are determined based on a primary reference batch and validated for accuracy (91–104% in one study).
  • Establishing the Calibration Curve: The standards, with known concentrations, are run in each ELISA alongside patient samples to generate a standard curve. The curve’s linearity and accuracy (consistent with strict regulatory guidelines such as EMA/FDA) are analyzed over repeated assays to ensure robustness and reproducibility.
  • Reference Controls: Biosimilar-based standards serve as reference controls. They are used to validate the assay’s performance and ensure that measured values in the test samples are accurate relative to these known concentrations.
  • Bridging for PK Studies: Use of biosimilars as calibrators enables direct quantification of drug concentration, crucial for PK bridging studies that compare innovator drugs against biosimilars in serum.
  • Assay Sensitivity and Quantification: The established calibration curve and lower limit of quantification (LLoQ)—for example, as low as 0.5 ng/mL for alemtuzumab—define the assay’s dynamic range to detect peak and sub-lympholytic drug levels.

Additional Relevant Information:

  • Assay Standardization: For commercial or clinical ELISA kits, calibration standards are often validated against international standards (e.g., NIBSC/WHO) and innovator drugs to ensure equivalence.
  • Assay Matrix Matching: Calibration standards are prepared in the same matrix (e.g., neat human serum) as study samples to correct for potential matrix effects, contributing to reliable recovery and quantitative accuracy.
  • Precision Metrics: Stringent requirements for intra- and inter-assay coefficient of variation (CV) and accuracy ensure assay reliability for clinical and research purposes.

In summary, biosimilar-grade Alemtuzumab standards act as crucial calibration and control reagents in PK ELISA protocols, anchoring quantification and assay validation by matching lot, matrix, and concentration characteristics to those expected in real-world serum samples.

Biopharma companies employ a comprehensive battery of analytical assays to confirm both structural and functional similarity between proposed biosimilars and their reference products. This analytical characterization forms the foundation of biosimilar development and regulatory approval.

Structural Similarity Assays

The structural characterization begins with primary amino acid structure analysis to confirm sequence identity between the biosimilar and reference product. Companies utilize advanced analytical techniques including circular dichroism and nuclear magnetic resonance spectroscopies to analyze higher-order protein structure.

Peptide mapping serves as a crucial tool for detecting structural differences, particularly in glycosylation profiles between products. Mass spectrometry and other orthogonal methods are employed to identify posttranslational modifications, which can significantly impact protein function. Manufacturers also conduct rigorous purity and impurity profiling to ensure comparable quality between the biosimilar and reference product.

The analytical approach involves head-to-head comparisons using multiple lots of both the proposed biosimilar and reference product, with results required to fall within appropriate limits, ranges, or distributions. Companies often apply multiple complementary techniques or orthogonal methods to better characterize molecular properties and more sensitively assess for potential differences.

Functional Similarity Assays

Functional assays serve as the crucial link between structural data and clinical expectations, answering whether any observed structural differences translate into functional significance. These assays fall into two primary categories:

Binding Assays evaluate the biosimilar's ability to bind to its intended target with equivalent affinity. For monoclonal antibodies, this includes Fc receptor binding assays that assess binding to key immune receptors like FcγRIIIa. These assays can demonstrate that even minor structural differences, such as slight variations in glycosylation profiles, do not impact functional performance.

Potency Assays measure the biological activity and mechanism-of-action bioassays that evaluate the drug's intended therapeutic function. Enzyme kinetics studies assess the catalytic activity of therapeutic enzymes, while other biological assays evaluate various functional endpoints relevant to the specific therapeutic protein.

Risk-Based Approach to Testing

Manufacturers rank molecular properties by their risk of impact to the product's activity, pharmacokinetics and pharmacodynamics, safety, efficacy, or immunogenicity. This risk assessment determines which attributes are most critical for demonstrating biosimilarity, with particular focus placed on properties based on the protein's nature and mechanism of action.

The analytical studies must demonstrate that the proposed biosimilar and reference product are highly similar, with any structural differences shown to be functionally insignificant through comprehensive functional testing. This extensive characterization of the reference product establishes the standards against which the proposed biosimilar is evaluated.

Regarding the Leinco biosimilar specifically, the provided search results do not contain information about this particular product or its use in analytical studies. The analytical methods described represent general industry standards applied across all biosimilar development programs to establish the totality of evidence required for regulatory approval.

References & Citations

Indirect Elisa Protocol
FA
Flow Cytometry

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.